AAO advocacy’s first quarter of the 2024-2025 fiscal year had a positive work start in July as AAO President Dr. John Callahan, fellow AAO trustees Dr. Michael Durbin and Dr. Ken Webb, advocacy representatives Nathan Mick and Alex Campau, and CEO Trey Lawrence met in Washington, D.C. with key leaders at the U.S. Food & Drug Administration (FDA) with oversight on prescription medical devices, including clear aligners.
The following day, AAO leaders met directly with eight members of Congress and their staff, including members who signed the December 2022 letter to the Government Accountability Office (GAO) requesting the study of FDA and FTC oversight of DTC devices. These meetings provided timely opportunities to relay what the delegation learned from the FDA the day before and consider next steps at the Congressional level for patient protections.
In August, the Council on Government Advocacy (COGA) and the AAOPAC Board held their annual in-person meeting at the AAO headquarters in St. Louis to work on grassroots strategy and AAO Political Action Committee fundraising efforts, and to approve new National Advocacy Network volunteers.
State advocacy continues to yield success with teledentistry legislation signed into law in Florida and Illinois. Work continues on specialty licensing and advertising and workforce solutions in Michigan and Maryland, with recent successes in North Dakota and the District of Columbia.
A growing number of AAO members are investing in AAOPAC to help fuel our advocacy success not only in Washington, D.C. but in states throughout the country. Please consider making a contribution for 2024 now at AAOPAC.org.
Read more recent AAOPAC, federal advocacy, state advocacy, and media advocacy news from this quarter.
View the 1st Quarter 2024-25 Dashboard
